Matthew J. Barrett
A5045749200- Parkinson's Disease Mechanisms and Treatments
- Neurological disorders and treatments
- Dementia and Cognitive Impairment Research
- Lysosomal Storage Disorders Research
- Ginkgo biloba and Cashew Applications
- Nuclear Receptors and Signaling
- Autism Spectrum Disorder Research
- Alzheimer's disease research and treatments
- Cellular transport and secretion
- Genetic Neurodegenerative Diseases
- Cholinesterase and Neurodegenerative Diseases
- Auditing, Earnings Management, Governance
- Attention Deficit Hyperactivity Disorder
- Financial Reporting and Valuation Research
- Health Systems, Economic Evaluations, Quality of Life
- Genomic variations and chromosomal abnormalities
- Pharmaceutical Practices and Patient Outcomes
- Environmental Education and Sustainability
- Restless Legs Syndrome Research
- EEG and Brain-Computer Interfaces
- Functional Brain Connectivity Studies
- Frailty in Older Adults
- Indigenous Health, Education, and Rights
- Indigenous Studies and Ecology
- Neuroscience and Neural Engineering
Virginia Commonwealth University
2020-2025
ExxonMobil (United States)
2023-2025
Dorset County Hospital
2025
Neurology, Inc
2025
University of Iowa
2024
Rutgers, The State University of New Jersey
2024
University of Pennsylvania
2024
HealthPartners
2024
Mayo Clinic in Florida
2017-2024
University Health System
2024
Abstract Digital health technologies can provide continuous monitoring and objective, real-world measures of Parkinson’s disease (PD), but have primarily been evaluated in small, single-site studies. In this 12-month, multicenter observational study, we whether a smartwatch smartphone application could measure features early PD. 82 individuals with early, untreated PD 50 age-matched controls wore research-grade sensors, smartwatch, while performing standardized assessments the clinic. At...
Estimates of the penetrance LRRK2 G2019S vary widely (24%-100%), reflective differences in ascertainment, age, sex, ethnic group, and genetic environmental modifiers.The kin-cohort method was used to predict 2,270 relatives 474 Ashkenazi Jewish (AJ) Parkinson disease (PD) probands Michael J. Fox AJ Consortium New York Tel Aviv, Israel. Patients with PD were genotyped for mutation at least 7 founder GBA mutations. carriers excluded. A validated family history interview, including age onset...
ABSTRACT The phenotype of Parkinson's disease (PD) in patients with and without leucine‐rich repeat kinase 2 ( LRRK2 ) G2019S mutations reportedly is similar; however, large, uniformly evaluated series are lacking. objective this study was to characterize the clinical Ashkenazi Jewish (AJ) PD carriers mutation. We studied 553 AJ patients, including 65 who were previously reported, from three sites (two New York one Tel‐Aviv). Glucocerebrosidase GBA mutation excluded. Evaluations included...
Sleep dysfunction is common and disabling in persons with Parkinson's Disease (PD). Exercise improves motor symptoms subjective sleep quality PD, but there are no published studies evaluating the impact of exercise on objective outcomes. The goal this study was to determine if high-intensity rehabilitation combining resistance training body-weight interval training, compared a hygiene control improved outcomes PD.Persons PD (Hoehn & Yahr stages 2-3; aged ≥45 years, not regular program) were...
Digital measures may provide objective, sensitive, real-world of disease progression in Parkinson's (PD). However, multicenter longitudinal assessments such are few. We recently demonstrated that baseline gait, tremor, finger tapping, and speech from a commercially available smartwatch, smartphone, research-grade wearable sensors differed significantly between 82 individuals with early, untreated PD 50 age-matched controls. Here, we evaluated the change these over 12 months observational...
It is widely cited that dementia occurs in up to 80% of patients with Parkinson disease (PD), but studies reporting such high rates were published over two decades ago, had relatively small samples, and other limitations. We aimed determine long-term risk PD using data from large, ongoing, prospective, observational studies.
We investigated system-level corticostriatal changes in a human model of premotor Parkinson disease (PD), i.e., healthy carriers the G2019S LRRK2 mutation that is associated with markedly increased, age-dependent risk developing PD.We compared 37 asymptomatic (age range 30-78 years) 32 matched, nonmutation 30-74 years). Using fMRI, we tested hypothesis connectivity PD shifts from severely affected to less striatal subregions, as shown previously symptomatic PD. Specifically, predicted PD,...
To determine the evolution of numerous neuropsychiatric symptoms and cognitive abilities in Parkinson disease from onset.
Using the iterative process of action research, we identify six portals understanding, called threshold concepts, which can be used as curricular guideposts to disrupt socially constituted separation, and hierarchy, between humans more-than-human. The concepts identified in this study provide focal points for a curriculum transformative sustainability learning (1) acknowledges non-human agency; (2) recognizes that capacity work with multiple ways knowing is required effectively engage...
Background The objective of this study was to confirm whether an association between handedness and the side symptom onset exists evaluate impact on specific clinical characteristics Parkinson's disease (PD). Methods 1173 PD patients were identified from a database. Patients with asymmetrical (n=1015) divided into those dominant-side non-dominant-side onset, two subgroups compared. Results In our sample, 86.5% presented asymmetrically. There significant initial symptom; that is, dominant...
To assess cognitive abilities of healthy first-degree relatives Ashkenazi patients with Parkinson disease (PD), carriers the G2019S mutation in LRRK2 gene.In this observational study, 60 consecutive (aged 50.9 ± 6.2 years; 48% male; 30 carriers) were assessed using a computerized program, Montreal Cognitive Assessment questionnaire, Unified Parkinson's Disease Rating Scale Part III, and Geriatric Depression Scale.G2019S scored significantly lower on executive function index (p = 0.04)...
Determining baseline predictors of future psychosis in Parkinson disease (PD) may identify those at risk for more rapidly progressive disease, i.e., a malignant PD subtype.This cohort study evaluated 423 patients with newly diagnosed collected as part the Parkinson's Progression Markers Initiative. Psychotic symptoms were assessed Movement Disorders Society-Unified Disease Rating Scale item 1.2, which assesses hallucinations and over past week. At baseline, participants completed Scales...
Objective A major contributor to dementia in Parkinson disease (PD) is degeneration of the cholinergic basal forebrain. This study determined whether nucleus 4 (Ch4) density associated with cognition early and more advanced PD. Methods We analysed brain MRIs neuropsychological test scores for 228 newly diagnosed PD participants from Parkinson’s Progression Markers Initiative (PPMI), 101 healthy controls PPMI 125 patients a local retrospective cohort. Cholinergic forebrain nuclei densities...
Background: Research criteria for prodromal dementia with Lewy bodies (DLB) were published in 2020, but little is known regarding DLB clinical settings. Methods: We identified non-demented participants without neurodegenerative disease from the National Alzheimer’s Coordinating Center Uniform Data Set who converted to at a subsequent visit. Prevalence of neuropsychiatric and motor symptoms examined up 5 years prior diagnosis. Results: The sample included 116 clinically diagnosed 348 age...
Abstract Leucine rich repeat kinase ( LRRK2 ) G2019S mutations are presumed to cause PD through a toxic gain of function the protein kinase. Small molecule inhibitors have been developed for treatment certain cancers, and some antioncogenic agents such as sunitinib, may nonspecifically inhibit . Few studies, however, assessed cancer risk in mutation carriers. To explore this risk, we evaluated records Ashkenazi Jewish (AJ) patients participating genetic research. Charts were reviewed 163...
<h3>Objective</h3> To examine nonmotor outcomes and correlates of quality life (QoL) 3 12 months after unilateral focused ultrasound thalamotomy in tremor-dominant Parkinson disease (TDPD). <h3>Methods</h3> Twenty-seven patients with TDPD a double-blind, sham-controlled, randomized clinical trial underwent comprehensive neuropsychological evaluations. These included assessment mood, behavior, QoL at baseline, months, post crossover the sham group, active treatment. We used Mann-Whitney...
In this paper, we contribute to land education research by focusing on the Torres Strait Islands in Coral Sea at far north of tip Cape York, Australia. We describe Islander concept Country and Ailan Kastom (translated as ‘Island Custom’). then analyse some ways which settler colonisation has challenged these knowing being. Our inquiry looks how is positioned within two contemporary Australian examples environmental education: firstly, new Curriculum cross-curriculum priorities that mandate...
To delineate the natural history, diagnosis, and treatment response of Parkinson disease (PD) in individuals with 22q11.2 deletion syndrome (22q11.2DS), to determine if these patients differ from those idiopathic PD.In this international observational study, we characterized clinical neuroimaging features 45 22q11.2DS PD (mean follow-up 7.5 ± 4.1 years).22q11.2DS had a typical male excess (32 male, 71.1%), presentation progression hallmark motor symptoms, reduced striatal dopamine...